Teva, Viatris Handed Second Bite At Overturning Core US Invega Sustenna Patent
New Jersey Court’s Obviousness Find Wiped Out And Remanded For Further Analysis
Executive Summary
Teva and Viatris hold firm ambitions in the long-acting schizophrenia space, and have just secured a win in their endeavors by convincing the US Court of Appeals for the Federal Circuit that a lower court erred in its analysis of whether a key Invega Sustenna patent was obvious.